Evox Oxford

Evox Therapeutics, an Oxford University spinout working to develop ways in which life-saving drugs are delivered, has raised £35m from investors.

According to The Sunday Times the round, which values the company at approximately £85m, drew support from backers including GV – the VC arm of Alphabet, Google’s parent company. GV contributed £10m to the round.

Other investors included Cowen Healthcare, Panacea Healthcare Venture, Borealis Ventures, Oxford University and Oxford Sciences Innovation.

Evox Therapeutics was set up a couple of years ago by academics. The company is led by  Dr Tony de Fougerolles, the former chief science officer of BioTech company Ablynx.

De Fougerolles, CEO of Evox, said: “We are very pleased for the support of both our existing and new investors who participated in this Series B financing. Over the past several years we have continued to expand the reach of our exosome platform, translating that knowledge into impactful therapeutics for our internal pipeline and for partners. We have also vigorously expanded our robust intellectual property portfolio, built our internal R&D teams, and put in place advisory boards who are offering deep insights as we advance key programmes towards clinical development.

“We are excited by the inherent transformational potential of our exosome technology, which significantly improves and enables the delivery of a wide range of therapeutic molecules, including antibodies, proteins, nucleic acids, and small molecules. This additional funding will enable us to advance our pipeline of novel exosome-based therapeutics towards the clinic and allow continued expansion of our world-leading exosome platform,” he added.

Evox previously raised £10m as part of a Series A round.